Inappropriate activation of the epidermal growth factor receptor (EGFR) signaling pathway readily promotes anti-hormonal treatment failure in breast cancer[6-8]; EGFR over-expression reportedly decreases sensitivity to endocrine therapy in breast cancer patients[9]. This evidence concerns the gene EGFR and breast cancer.